JAG1 and cancer: Nanoparticles have reached clinical testing for cancer vaccines based on liposomes,33–35 virus-like nanoparticles36 and nanogels.37 The CPQ adjuvant system, which is based on CoPoP liposome technology that enables spontaneous self-assembly of Ags, has previously been demonstrated to enhance the immunogenicity of soluble protein Ags derived from microbial pathogens,38–40 CoPoP liposomes recently have proceeded into human clinical trials (clinicaltrials.gov # NCT04783311) for a SARS-CoV-2 vaccine.